Investor Alert

Market Pulse Archives

July 13, 2020, 6:41 a.m. EDT

ACell sets IPO terms, could be valued at up to $362.8 million

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Renaissance IPO ETF (IPO)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

ACell Inc. set terms of its initial public offering, in which the Maryland-based regenerative medicine company focused on severe wounds treatment looks to raise up to $80 million and be valued at up to $362.8 million. The company is selling 5 million shares in the IPO, which is expected to price between $14 and $16 a share. There will be 22.68 million shares outstanding after the IPO. UBS, Barclays, RBC Capital Market and SunTrust Robinson Humphrey are the lead underwriters. The recorded a net loss of $2.7 million on revenue of $23.68 million over the three months ended March 31, after net income of $66,000 on revenue of $24.15 million in the same period a year ago. The company is looking to go public at a time that the Renaissance IPO ETF /zigman2/quotes/207665280/composite IPO +4.48% has soared 61.7% over the past three months while the S&P 500 /zigman2/quotes/210599714/realtime SPX +1.49% has advanced 15.3%.

US : U.S.: NYSE Arca
$ 56.45
+2.42 +4.48%
Volume: 151,964
May 14, 2021 4:00p
+61.35 +1.49%
Volume: 1.91B
May 14, 2021 5:02p

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.